NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Esperion Therapeutics, Inc. (ESPR) Stock Analysis

Esperion Therapeutics, Inc. (ESPR) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

ESPR

$3.18

+$0.06 (+1.92%)

Last trade July 13, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ESPR with… →

ESPR Key Statistics

As of Jul 13, 2026
Trading
Open
$3.18
Previous Close
$3.12
52-Week Range
0.79–4.18
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.91
Valuation
Market Cap
$803.19M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.68
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.92
EPS (ttm)Profit attributable to each share over the last twelve months.
0.00
Financials (FY)
Revenue (FY)
$403.14M+21.31%
Net Income (FY)
−$22.68M
Profit marginThe share of revenue left as profit after all costs and taxes.
−1.77%
1-Year Return
+167.23%
Dividend and dates
Avg Volume
11.68M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ESPR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−14.05%
2025+68.18%
2024 (partial year)+1.38%

As of July 13, 2026.

ESPR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$403.14M−$22.68M−5.6%
2024$332.31M−$51.75M−15.6%
2023$116.33M−$209.25M−179.9%
2022$75.48M−$233.66M−309.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$403.14M$273.91M$60.27M−$22.68M−5.6%
2024$332.31M$263.71M$54.40M−$51.75M−15.6%
2023$116.33M$73.07M−$155.56M−$209.25M−179.9%
2022$75.48M$48.51M−$179.50M−$233.66M−309.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ESPR Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricESPRDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.922.3016% below
Profit margin−1.77%−3.14%1.4 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Esperion Therapeutics, Inc. (ESPR) is capitalised at $803.19M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 294 employees.

The most recent close on file for ESPR is $3.18, dated July 13, 2026. That is +$0.06 (+1.92%) against the previous close. The 52-week range on file runs from $0.79 to $4.18. The latest close sits 302.53% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $403.14M. Against the prior fiscal year total of $332.31M, that is a change of +21.31%. The same year closed with a net loss of $22.68M. The reported profit margin is −1.78%. That is 1.4 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to 0.

Across the 4 fiscal years on file, revenue moves from $75.48M in 2022 to $403.14M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 10.68. Measured against sales, the shares trade at 1.92 times revenue. On price-to-sales that is 16.37% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.91. Daily returns over the trailing 1 year annualize to a volatility of 96.72%. The trailing one-year price return is +167.23%. The stored price history starts on December 19, 2024, and the total return since then is +46.54%.

Growth & Income

No dividend is on file for ESPR.

2026 is still running; the price is −14.05% year to date. The record holds one complete calendar year, 2025, which returned +68.18%.

Peer Comparison

Esperion Therapeutics, Inc. (ESPR) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Esperion Therapeutics, Inc. ESPR $803.19M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Esperion Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 13, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Visit website →